{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:51:16Z","timestamp":1792785076964,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cofactor Genomics","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"https:\/\/ror.org\/031fg5f22","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lung cancer remains the leading cause of cancer mortality worldwide. Immune checkpoint inhibitors (ICI) targeting PD-1\/PD-L1 have significantly improved outcomes in a subset of patients. OncoPrism, a clinical test employing a multidimensional predictive RNA-based immune biomarker, was evaluated for predicting immune checkpoint inhibitor benefit in non-small cell lung cancer (NSCLC) patients. This study evaluated OncoPrism in 1487 patients across four NSCLC cohorts: one PD-L1 inhibitor cohort (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009195), one PD-1 inhibitor cohort (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200989), and two non-ICI cohorts (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009193 and\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091010). In the PD-L1 inhibitor cohort, OncoPrism predicted progression-free survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001) and overall survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.043). In the PD-1 inhibitor cohort, an observational clinical trial, PREDAPT, enrolling patients from 17 healthcare systems, OncoPrism predicted overall response rate (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.008), progression-free survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004), and overall survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.011). PD-L1 Tumor Proportion Score (TPS) was not predictive of response, progression-free survival, or overall survival. OncoPrism did not predict overall survival across two non-ICI NSCLC cohorts (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.54,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.73), suggesting the test is specifically predictive of ICI benefit rather than being prognostic with more limited clinical utility. Overall, the data show OncoPrism high patients have two to three-fold greater overall response rate, progression-free survival, and overall survival compared to those in other OncoPrism groups. These results underscore the impact of OncoPrism to address the current unmet need for ICI response prediction in NSCLC. This trial was registered with ClinicalTrials.gov, number NCT04510129, on 10 August 2020.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01632-6","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:05:08Z","timestamp":1785359108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validation of a tissue-based predictive RNA test for immunotherapy benefit in NSCLC: the PREDAPT study"],"prefix":"10.1038","volume":"10","author":[{"given":"Kevin C.","family":"Flanagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Earls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Hiken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Wellinghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Ponder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Pemberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlan K.","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Welaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Pippas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"D\u2019Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwei","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren L.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Slim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Saccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd D.","family":"Shenkenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel D.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Sonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Azzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Bank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Kossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"James","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Hellyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard L.","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Duncavage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarret I.","family":"Glasscock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"1632_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1632_CR2","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"1632_CR3","doi-asserted-by":"publisher","first-page":"e2335813","DOI":"10.1001\/jamanetworkopen.2023.35813","volume":"6","author":"CC Su","year":"2023","unstructured":"Su, C. C. et al. Overall survival among patients with de novo stage IV metastatic and distant metastatic recurrent non-small cell lung cancer. JAMA Netw. Open 6, e2335813 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1632_CR4","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti, A. K., Klein, A. B., Cotarla, I., Seal, B. & Chou, E. Update of incidence, prevalence, survival, and initial treatment in patients with non\u2013small cell lung cancer in the US. JAMA Oncol. 7, 1824 (2021).","journal-title":"JAMA Oncol."},{"key":"1632_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader, N. et al. The effect of advances in lung-cancer treatment on population mortality. N. Engl. J. Med. 383, 640\u2013649 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1632_CR6","doi-asserted-by":"crossref","unstructured":"Reck, M. et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%. J. Clin. Oncol. 39, 2339\u20132349 (2021).","DOI":"10.1200\/JCO.21.00174"},{"key":"1632_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei, H. et al. Five-year outcomes from the randomized, phase III trials Checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J. Clin. Oncol. 39, 723\u2013733 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1632_CR8","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino, M. C. et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J. Clin. Oncol. 41, 1992\u20131998 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1632_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41379-021-00932-5","volume":"35","author":"LM Sholl","year":"2022","unstructured":"Sholl, L. M. Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer. Mod. Pathol. 35, 66\u201374 (2022).","journal-title":"Mod. Pathol."},{"key":"1632_CR10","doi-asserted-by":"crossref","unstructured":"Catalano, M. et al. Immunotherapy-related biomarkers: confirmations and uncertainties. Crit. Rev. Oncol. Hemat. 192, 104135 (2023).","DOI":"10.1016\/j.critrevonc.2023.104135"},{"key":"1632_CR11","unstructured":"National Comprehensive Cancer Network. Non\u2013Small Cell Lung Cancer (NCCN Clinical Practice Guidelines in Oncology), Version 1.2026. NCCN.org (2025)."},{"key":"1632_CR12","first-page":"e45","volume":"43","author":"DH Owen","year":"2025","unstructured":"Owen, D. H. et al. Therapy for stage IV non\u2013small cell lung cancer without driver alterations: ASCO living guideline, version 2025.1. J. Clin. Oncol. 43, e45\u2013e58 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1632_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks, L. E. et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 358\u2013376 (2023).","journal-title":"Ann. Oncol."},{"key":"1632_CR14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jtho.2024.03.002","volume":"19","author":"B Ricciuti","year":"2024","unstructured":"Ricciuti, B. & Garassino, M. C. Precision Immunotherapy for STK11\/KEAP1-Mutant NSCLC. J. Thorac. Oncol. 19, 877\u2013882 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"1632_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jtho.2023.10.004","volume":"19","author":"SR Yang","year":"2024","unstructured":"Yang, S. R. et al. Microsatellite instability and mismatch repair deficiency define a distinct subset of lung cancers characterized by smoking exposure, high tumor mutational burden, and recurrent somatic MLH1 inactivation. J. Thorac. Oncol. 19, 409\u2013424 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"1632_CR16","doi-asserted-by":"crossref","unstructured":"Merino, D. M. et al. Establishing guidelines to harmonize tumor mutational burden (TMB): In silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J. Immunother. Cancer 8, e000147 (2020).","DOI":"10.1136\/jitc-2019-000147"},{"key":"1632_CR17","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ejca.2008.03.006","volume":"44","author":"CNAM Oldenhuis","year":"2008","unstructured":"Oldenhuis, C. N. A. M., Oosting, S. F., Gietema, J. A. & de Vries, E. G. E. Prognostic versus predictive value of biomarkers in oncology. Eur. J. Cancer 44, 946\u2013953 (2008).","journal-title":"Eur. J. Cancer"},{"key":"1632_CR18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1634\/theoncologist.2015-0279","volume":"21","author":"F Ciardiello","year":"2016","unstructured":"Ciardiello, F. et al. Awareness, understanding, and adoption of precision medicine to deliver personalized treatment for patients with cancer: a multinational survey comparison of physicians and patients. Oncologist 21, 292\u2013300 (2016).","journal-title":"Oncologist"},{"key":"1632_CR19","unstructured":"Biomarker Testing Mandate, Blue Cross Blue Shield Medical Coverage Policy. 2024."},{"key":"1632_CR20","unstructured":"American Cancer Society. Survey Findings Summary: Understanding Provider Utilization of Cancer Biomarker Testing Across Cancers. 2021. Accessed 12, 2025. https:\/\/www.fightcancer.org\/sites\/default\/files\/national_documents\/provider_utilization_of_biomarker_testing_polling_memo_dec_2021.pdf."},{"key":"1632_CR21","doi-asserted-by":"crossref","unstructured":"Flanagan, K. C. et al. Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study. J. Immunother. Cancer 12, e009573 (2024).","DOI":"10.1136\/jitc-2024-009573"},{"key":"1632_CR22","doi-asserted-by":"crossref","unstructured":"Hiken, J. et al. Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent\/metastatic head and neck squamous cell carcinoma. BMC Cancer 25, 21 (2025).","DOI":"10.1186\/s12885-024-13362-8"},{"key":"1632_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255\u2013265 (2017).","journal-title":"Lancet"},{"key":"1632_CR24","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1632_CR25","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Weinstein, J. N. et al. The cancer genome atlas pan-cancer analysis project. Nat. Genet. 45, 1113\u20131120 (2013).","journal-title":"Nat. Genet."},{"key":"1632_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jmoldx.2020.01.009","volume":"22","author":"I Schillebeeckx","year":"2020","unstructured":"Schillebeeckx, I. et al. Analytical performance of an immunoprofiling assay based on RNA models. J. Mol. Diagn. 22, 555\u2013570 (2020).","journal-title":"J. Mol. Diagn."},{"key":"1632_CR27","doi-asserted-by":"publisher","unstructured":"Therneau, T. M. & Grambsch, P. M. Modeling survival data: extending the Cox model. https:\/\/doi.org\/10.1007\/978-1-4757-3294-8 (2000).","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"1632_CR28","unstructured":"Therneau, T. M. Survival Analysis [R package survival version 3.5-5]. https:\/\/CRAN.R-project.org\/package=survival (2023)."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01632-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01632-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01632-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:04:53Z","timestamp":1791245093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01632-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1632"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01632-6","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.C.F., J.E., J.H., R.L.W., M.M.P., K.P., and J.I.G. are employed by and have stock interests in Cofactor Genomics. J.A.H. has participated on advisory boards for Daiichi Sankyo and Boehringer Ingelheim. H.L.McL. consults for and has stock interest in Cofactor Genomics. E.J.D. consults for and has stock interest in Cofactor Genomics and received speaker fees from Blueprint Medicines and Syndax Pharmaceuticals. He also consults for and receives royalties from Caris Life Sciences and consults for Geneoscopy and Bruker Life Sciences. All others declare no competing financial or non-financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"369"}}